首页 正文

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy

{{output}}
Management of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved substantially with the integration of novel targeted and immune-based therapies. Agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) have demonstrate... ...